Direct Differentiation of Somatic Cells into Insulin-Producing Cells

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for directly converting somatic cells into insulin-producing cells without gene transfer are limited, often requiring specific gene introduction into endodermal cells with a close developmental lineage.

Innovation Solution

An in vitro process involving the use of low molecular weight compounds, specifically an RSK inhibitor (BRD7389 or BI-D1870), a GSK3 inhibitor (CHIR99021), and a cAMP inducer (forskolin), to directly differentiate somatic cells, such as fibroblasts or mesenchymal stem cells, into insulin-producing cells without serum in the differentiation medium.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If gene transfer is used to convert somatic cells into insulin-producing cells, then conversion efficiency is improved, but process complexity and safety risks increase

Engineering Contradiction:
Improveconversion efficiencyVSAvoidprocess complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The invention extracts and eliminates the gene transfer step from the conventional process. Instead of introducing exogenous genes, the method uses low molecular weight compounds to directly induce somatic cells to differentiate into insulin-producing cells, thereby simplifying the process and removing safety concerns associated with genetic modification

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention substitutes the mechanical/genetic intervention (gene transfer) with a chemical intervention (low molecular weight compounds). Specifically, compounds such as CHIR99021 (GSK3β inhibitor), forskolin (cAMP inducer), and BRD7389 (RSK inhibitor) are used to chemically induce differentiation, replacing the need for viral vectors or transfection methods

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If specific genes are introduced into endodermal cells, then insulin-producing cell formation is improved, but cell type specificity requirements worsen

Engineering Contradiction:
Improveinsulin-producing cell formationVSAvoidcell type specificity
Core Design Contradiction:
ProductivityVSAdaptability or versatility

Solution Approach 1:

The invention makes the differentiation process universal by demonstrating that low molecular weight compounds can induce insulin-producing cells from multiple types of somatic cells, not just endodermal cells. The method has been successfully applied to fibroblasts, adipocytes, and other mesenchymal cells, showing broad applicability across different cell lineages

Inventive Principle:
Principle #6Universality (Multi-functionality)

Solution Approach 2:

The invention changes the differentiation parameters by using small molecule compounds that target specific signaling pathways (Wnt/β-catenin, cAMP, RSK) rather than relying on cell type-specific transcription factors. This parameter change allows cells from different lineages to be redirected toward insulin-producing cell fate through common molecular mechanisms

Inventive Principle:
Principle #35Parameter changes

3Productivity

If conventional differentiation methods are used, then cell production is achieved, but secretion ability is insufficient

Engineering Contradiction:
Improvecell productionVSAvoidsecretion ability
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The invention performs preliminary action by using low molecular weight compounds to pre-condition and prime the cells during the differentiation process. The compounds CHIR99021, forskolin, and BRD7389 are applied in a specific sequence and combination to prepare the cells for optimal insulin production and secretion capacity before final differentiation

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention uses a composite approach by combining multiple low molecular weight compounds that target different signaling pathways simultaneously. This composite treatment (GSK3β inhibitor + cAMP inducer + RSK inhibitor) creates a synergistic effect that enhances both cell differentiation and insulin secretion ability beyond what single compounds can achieve

Inventive Principle:
Principle #40Composite materials

Data Source

PatentEP3882339B1Method for producing insulin-producing cells
Publication Date: 2025.01.22 KATAOKA
  • EP3882339B1 patent drawingFigure 1
  • EP3882339B1 patent drawingFigure 2
  • EP3882339B1 patent drawingFigure 3

AI summary

It is a main object of the present invention to provide a process for producing an insulin-producing cell from a somatic cell without performing artificial gene transfer, an insulin-producing cell obtained from the process, or a composition comprising a combination of chemical substances that can be used for the process. The present invention can include, for example: a process for producing an insulin-producing cell from a somatic cell by direct differentiation induction, comprising a step of culturing a somatic cell in the presence of an RSK inhibitor; an insulin-producing cell obtained from the process; and a composition for producing an insulin-producing cell from a somatic cell by directly inducing differentiation, comprising an RSK inhibitor. The insulin-producing cells obtained according to the present invention are useful in regenerative medicine and the like.